Similar Stories to Novartis And Exelixis Are Big Market Movers on Bing News

NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market: NYSE Novartis AG, up $3.43 to $93.47 The drug developer presented positive data for a potential heart-failure drug and will ask for approval by the end of the year. Las Vegas Sands Corp., down $3.41 to $63.10 The casino operator and its gambling company peers experienced a decline in revenue from the gambling hub Macau during August. Cloud Peak Energy Inc., down $1.27 to $14.44 The coal company lowered its coal shipment and adjusted earnings guidance for 2014, citing rail issues and weather impacts. Crown Holdings Inc., up $1.85 to $50.12 The packaging products company is buying the Mexican can packaging business of brewer Heineken for just under $1.23 billion. Nasdaq Exelixis Inc., down $2.29 to $1.85 The biotechnology company said its potential treatment for prostate cancer failed to meet a key goal in a late-stage study. Conns Inc., down $13.83 to $31 The consumer goods retailer reported second-quarter profit below Wall Street expectations and cut its full-year profit guidance. Norwegian Cruise Line Holdings Ltd., up $3.68 to $36.99 The cruise line will buy Prestige Cruises International for about $3 billion and expects to close the deal in the fourth quarter. Acadia Pharmaceuticals Inc., up $2.63 to $26.61 The biotechnology company received a special FDA designation for its potential Parkinson's disease psychosis treatment, Nuplazid.Read more on NewsOK.com

BING NEWS:
  • Buy Rating Affirmed for Exelixis Amid Solid Revenue and Strategic Growth Initiatives
    H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of $28.00. Robert Burns has given his Buy rating due to a combination of ...
    05/2/2024 - 5:26 pm | View Link
  • Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript
    Q1 2024 Earnings Call Transcript April 30, 2024 Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.17 EPS, expectations were $0.28. EXEL isn’t one of the 30 most popular stocks among ...
    05/2/2024 - 8:50 am | View Link
  • Exelixis: With Patent Litigation Decision Due Soon, There Are Options
    Exelixis successfully implements Farallon's restructuring suggestions. Multiple billions of potential revenue are at stake. Find out why EXEL stock is a Buy.
    05/2/2024 - 5:28 am | View Link
  • The Analyst Verdict: Exelixis In The Eyes Of 5 Experts
    For valuable insights into Exelixis's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings ...
    05/1/2024 - 3:02 am | View Link
  • Exelixis (EXEL) Q1 2024 Earnings Call Transcript
    My name is Towanda, and I will be your operator today. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to your host for today, Mr. Varant ...
    04/30/2024 - 5:00 pm | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Living News